Avellino introduced the world's first DNA exam that confirms the presence of genetic indicators that are positively associated with corneal diseases, providing life-changing information for patient treatment decisions and follow-up care.
We are also pioneering CRISPR gene editing technology to manage and potentially cure diseases, such as lattice dystrophy, granular corneal dystrophy, and Reis-Bucklers dystrophy.
Avellino Labs is a genetic services provider specializing in genetic diagnostics, data, and therapy development. Genetic tests like ours allow patients to discover their diseases earlier, leading to greater treatment options and overall better care.
Headquartered in Silicon Valley, California, with additional operations in Korea, Japan, China, and the UK, Avellino Labs is bringing more personalized healthcare to people around the world.
Menlo Park, California: Avellino Labs, global biotechnology and genetic science innovators, announced the strategic addition of James (Jim) V. Mazzo to its board of directors.
While Avellino Labs continues to expand its research scope and apply its technology across multiple specialties and diseases, the partnership will further anchor Avellino Labs’ leadership in developing the science and setting the standard of genetic testing in ophthalmology.
Menlo Park, California: Avellino Labs, global biotechnology and genetic science innovators, announced Eric Bernabei as the company’s chief sales and marketing officer (CSMO).
The addition of Bernabei will further extend Avellino Labs’ leadership in global genetics and ophthalmic communities. Bernabei joins Avellino Labs with more than 20 years of product development and commercialization experience in ophthalmology.
Fill out the form below to be contacted by a team member of Avellino.